The U.S. peripheral nerve injuries market size is estimated to reach USD 712.5 million by 2030, registering a CAGR of 7.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is due to increasing healthcare expenditure in the U.S., an increasing prevalence of peripheral nerve injuries, growing focus on research and development, and a growing patient preference for minimally invasive procedures.
Technological advancements are revolutionizing the field of peripheral nerve injury treatment in the U.S. New and innovative treatment options such as nerve grafts, nerve conduits, and neurostimulation devices are providing improved outcomes and helping patients recover faster. Additionally, the use of minimally invasive surgical techniques, such as end-to-end nerve sutures and nerve decompression procedures, is gaining popularity among patients due to their benefits of faster recovery times. These advancements in medical technology are driving the growth of the market by providing more effective and less invasive treatment options.
Investments from key market players and collaborations between academia, industry, and healthcare institutions are driving R&D efforts, leading to the discovery of new treatment modalities. For instance, in June 2022, Vascudyne, Inc., a leading biotechnology company in regenerative medicine, was awarded a grant from Regenerative Medicine Minnesota for a research study titled "Production of a Peripheral Nerve Wrap Using Tissue Tubes from Regenerative Engineering." The study will be funded with USD 100,000 for one year, starting in June 2022, and will utilize Vascudyne's TRUE Tissue technology.
The COVID-19 pandemic has boosted the demand for minimally invasive procedures as it offer benefits such as shorter recovery times, potentially lower costs, better treatment options, and integration with telemedicine technologies. These factors may impact the market for U.S. peripheral nerve injuries positively.
Request a free sample copy or view report summary: U.S. Peripheral Nerve Injuries Market Report
Based on product/therapies, Nerve grafting segment dominated the U.S. peripheral nerve injury market share in 2024, accounting for 65.1%, owing to rapid advancements in nerve grafting techniques, such as autografts, allografts, and synthetic conduits
Based on surgery, direct nerve repair segment dominated the U.S. peripheral nerve injury market and held the largest revenue share of nearly 42.5%. It is considered the gold standard of surgical treatment for severe cases
Based on application, upper extremities segment held the largest U.S. peripheral nerve injury market share in 2024, accounting for 81.2%. increasing incidence of accidental falls and medical conditions, such as Guillain-Barre syndrome, diabetes, & carpal tunnel syndrome, is expected to drive the segment
Based on end use, hospitals segment dominated the market in 2024. Increasing number of hospitals and surgical cases in hospitals are expected to boost the segment.
Grand View Research has segmented the U.S. peripheral nerve injury market based on products/therapies, surgery, application, and end-use:
U.S. Peripheral Nerve Injuries Products/Therapies Outlook (Revenue, USD Million, 2018 - 2030)
Nerve Grafting
Autograft
Allograft
Stem Cell Therapy
Biomaterial
Nerve Conduit
Nerve Protector
Nerve Connector
Nerve Wraps
U.S. Peripheral Nerve Injuries Surgery Outlook (Revenue, USD Million, 2018 - 2030)
Direct Nerve Repair
Nerve Grafting
Stem Cell Therapy
Carpal Tunnel Release
Internal Neurolysis
Neurorrhaphy
U.S. Peripheral Nerve Injuries Surgery Outlook (Revenue, USD Million, 2018 - 2030)
Upper Extremities
Lower Extremities
U.S. Peripheral Nerve Injuries Surgery Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Clinics
Ambulatory Surgical Centers
Others
List of Key Players in the U.S. Peripheral Nerve Injuries Market
Axogen Corporation.
Stryker
Regenity
Integra LifeSciences Corporation.
TOYOBO CO., LTD.
Alafair Biosciences, Inc.
SYNOVIS MICRO COMPANIES ALLIANCE, INC., (BAXTER INTERNATIONAL INC.)
"The quality of research they have done for us has been excellent..."